Frequently Asked Questions about Cannabis

Untitled design - 2023-06-12T210854.698-min

Cannabis as a possible treatment for Hyperemesis Gravidarum (HG) has has not been well-researched. Many studies have small populations or lack scientific rigor. The strongest studies to date find significant concern with adverse fetal outcomes like preterm birth, neurodevelopmental disorders, and growth restricted babies. Cannabis  is not supported by the top OB societies including the American College of Obsteticians and Gynecologist (ACOG), Society of Maternal Fetal Medicine (SMFM), Society of Obstetricians and Gynaecologies of Canada (SOGC), or by MotherToMother due to the lack of safety evidence in the research.

In an effort to initiate progress researching safety and efficacy of cannabis in treating HG, HER published survey results, "Patterns of Use and Self-reported Effectiveness of Cannabis for Hyperemesis Gravidarum" in 2022.

Regular use of cannabis can lead to cannabinoid hyperemesis syndrome (CHS)? This may worsen HG and make HG less responsive to treatments. Antipsychotics such as haloperidol, olanzapine, or droperidol are more often used for CHS. Opioids are generally ineffective for the abdominal pain associated with CHS.

CHS is often diagnosed when nausea, vomiting, abdominal pain, and compulsive hot water bathing are noted in someone with current and long term cannabis use.

Read more in this systematic review abstract